Pre-made Placulumab benchmark antibody ( Single Domain Variable Fragment (VL) + Fc, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Placulumab biosimilar, Single Domain Variable Fragment (VL + Fc), Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-445-1mg	1mg	3090
GMP-Bios-ab-445-10mg	10mg	Inquiry
GMP-Bios-ab-445-100mg	100mg	Inquiry
GMP-Bios-ab-445-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Placulumab biosimilar, Single Domain Variable Fragment (VL + Fc), Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody
INN Name	Placulumab
Target	TNF
Format	Single Domain Variable Fragment (VL) + Fc
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica
Development Tech	na